Neurogene Inc (NGNE) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Neurogene Inc stock (NGNE) is currently trading at $20.90. Neurogene Inc PS ratio (Price-to-Sales) is 313.77. Analyst consensus price target for NGNE is $81.00. WallStSmart rates NGNE as Sell.
- NGNE PE ratio analysis and historical PE chart
- NGNE PS ratio (Price-to-Sales) history and trend
- NGNE intrinsic value — DCF, Graham Number, EPV models
- NGNE stock price prediction 2025 2026 2027 2028 2029 2030
- NGNE fair value vs current price
- NGNE insider transactions and insider buying
- Is NGNE undervalued or overvalued?
- Neurogene Inc financial analysis — revenue, earnings, cash flow
- NGNE Piotroski F-Score and Altman Z-Score
- NGNE analyst price target and Smart Rating
Neurogene Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Neurogene Inc (NGNE) · 5 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, institutional own.. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Neurogene Inc (NGNE) Key Strengths (2)
109.34% of shares held by major funds and institutions
Trading at 1.11x book value, attractively priced
Supporting Valuation Data
Neurogene Inc (NGNE) Areas to Watch (3)
Company is destroying shareholder value
Very expensive at 313.8x annual revenue
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
Neurogene Inc (NGNE) Detailed Analysis Report
Overall Assessment
This company scores 22/100 in our Smart Analysis, earning a F grade. Out of 5 metrics analyzed, 2 register as strengths (avg 9.0/10) while 3 fall into concern territory (avg 1.7/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own., Price/Book. Valuation metrics including Price/Book (1.11) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Price/Sales, Market Cap. Some valuation metrics including Price/Sales (313.77) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -42.20%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -42.20% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Price/Sales are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
NGNE Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
NGNE's Price-to-Sales ratio of 313.77x trades 303% above its historical average of 77.86x (87th percentile), historically expensive. The current valuation is 45% below its historical high of 573.71x set in Oct 2025, and 111961% above its historical low of 0.28x in Nov 2022. Over the past 12 months, the PS ratio has expanded from ~243.1x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Neurogene Inc (NGNE) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Neurogene Inc operates as a stable business with moderate growth and solid fundamentals.
Key Findings
Free cash flow is -20M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Volatility is elevated with a beta of 1.69, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Neurogene Inc.
Bottom Line
Neurogene Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 10:04:22 AM
About Neurogene Inc(NGNE)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Neurogene Inc. is a pioneering biotechnology firm specializing in the development of groundbreaking gene therapies aimed at addressing rare neurological disorders. With a focus on leveraging cutting-edge genetic medicine technologies, the company is committed to creating transformative treatments that meet significant unmet medical needs. Neurogene's robust pipeline of proprietary programs, coupled with its experienced leadership team, emphasizes its dedication to advancing the field of genetic therapies. As the company navigates its clinical development phases, it is well-positioned to enhance the quality of life for patients and families affected by genetic diseases.